Shares of Ralliant Corporation (NYSE:RAL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $61.90.
A number of research analysts recently weighed in on the stock. Barclays lifted their price objective on shares of Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday. Weiss Ratings restated a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Zacks Research upgraded shares of Ralliant from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Morgan Stanley lifted their price objective on shares of Ralliant from $45.00 to $68.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Truist Financial restated a “buy” rating and issued a $68.00 price objective (up from $53.00) on shares of Ralliant in a report on Wednesday.
Get Our Latest Stock Report on RAL
Insider Transactions at Ralliant
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in RAL. Viking Global Investors LP purchased a new position in Ralliant in the second quarter worth approximately $257,200,000. State Street Corp purchased a new position in Ralliant in the second quarter worth approximately $213,096,000. Millennium Management LLC lifted its stake in Ralliant by 172.4% in the fourth quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after acquiring an additional 3,147,660 shares during the last quarter. Norges Bank purchased a new position in Ralliant in the fourth quarter worth approximately $124,687,000. Finally, Invesco Ltd. lifted its stake in Ralliant by 90.1% in the third quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock worth $169,309,000 after acquiring an additional 1,835,128 shares during the last quarter.
Ralliant Trading Down 1.1%
Shares of RAL stock opened at $59.43 on Monday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.58 and a current ratio of 1.61. The stock has a market capitalization of $6.65 billion and a P/E ratio of -5.43. The company has a 50 day moving average price of $45.42 and a 200 day moving average price of $47.52. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $62.35.
Ralliant (NYSE:RAL – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. The firm had revenue of $534.60 million during the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The business’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities research analysts predict that Ralliant will post 2.63 EPS for the current fiscal year.
Ralliant Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be paid a $0.05 dividend. The ex-dividend date is Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s payout ratio is currently -1.83%.
About Ralliant
Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Further Reading
- Five stocks we like better than Ralliant
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.
